News
Entertainment
Science & Technology
Life
Culture & Art
Hobbies
News
Entertainment
Science & Technology
Culture & Art
Hobbies
Discover Latest #Financial support News, Articles and Videos with Contenting
1. "Fintech Funding Hits Record High in 2020, Thanks to Coronavirus Stimulus" - CNBC, December 28, 2020 https://www.cnbc.com/2020/12/28/fintech-funding-hits-record-high-in-2020-thanks-to-coronavirus-stimulus.html 2. "These Are the Government Programs That Can Provide Financial Support to Small Businesses During the Coronavirus Crisis" - Forbes, April 3, 2020 https://www.forbes.com/sites/alexkonrad/2020/04/03/these-are-the-government-programs-that-can-provide-financial-support-to-small-businesses-during-the-coronavirus-crisis/ 3. "Coronavirus: What is the Job Support Scheme and how do I claim financial support?" - The Independent, October 13, 2020 https://www.independent.co.uk/money/coronavirus-job-support-scheme-claim-furlough-self-employed-a9670096.html 4
Investing for Children this Christmas - UK Investor Magazine
Starting to save early can make a huge difference in your child’s future, providing them with the financial support they need for those big moments in life. “An investment account is for life, children, not just for Christmas, so that’s the way we’re going this year.” It’s not a line to endear you to your […]
Tallinna Vesi's investment plan for 2025 approved by the Supervisory Council - ForexTV
On 13 December, the Supervisory Council of Tallinna Vesi approved the company's investment plan for 2025, with planned investments amounting to €61 million. The aim of the investments is to ensure the continuity and future-proofing of assets required for the provision of a vital water service. "These investments are directed towards the company's core business to reduce the impact of water consumption on the environment, ensure the continuity of our services, and enable the development of urban spaces," explained Tarvi Thomberg, Chief Asset Management Officer at Tallinn Vesi. Key investments include the upgrading of treatment processes at the water treatment plant and the start of the implementation of new ozone technology. At the wastewater treatment plant, the mechanical screens will be reconstructed while the reconstruction of the secondary clarifiers continues. In 2025, we plan to construct and rehabilitate 45 km of pipelines. The investment plan is in line with the objectives of the Tallinn Public Water Supply and Sewerage Development Plan. The planned investments will be financed by Tallinna Vesi through a loan agreement signed in the second quarter of 2023 and by targeted financial support for investments in separate stormwater infrastructure. The loan agreement has been concluded with AS SEB Pank, Swedbank AS and OP Corporate Bank plc Estonian branch. The stock exchange release on this can be found here: AS Tallinna Vesi signed a loan agreement for a total amount of EUR 91 million. The investment plan includes the development of the separate stormwater infrastructure. The targeted financial support for investments in these new facilities has been approved by the Tallinn City Council and a contract with the City is about to be signed. "Stormwater investments are necessary to mitigate flooding risks, develop urban space and keep our wastewater treatment plant running sustainably during heavy rainfalls," said Thomberg. Investments made with targeted funding account for up to €5.6 million of the investments made in 2024. The volume of investments in 2024 will amount to 50 million euros. Kristiina Tamberg AS Tallinna Vesi Head of Communication and Marketing kristiina.tamberg@tvesi.ee +372 52 855 21
New CPP Payments for November 2024: What You Need to Know - TechBullion
The Canada Pension Plan (CPP) is a vital financial support system for millions of Canadians. Designed to provide income replacement in retirement, the CPP also extends benefits to those who are disabled or to the families of deceased contributors. As we approach the end of 2024, understanding the upcoming CPP payments dates 2024 and recent […]
Hampton Financial Corporation Announces 4th Quarter and Full Year Results for 2024 - ForexTV
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, Dec. 30, 2024 (GLOBE NEWSWIRE) -- Hampton Financial Corporation (“Hampton” or the “Company”, TSXV:HFC) today announced its financial results for the 4th Quarter and full year of fiscal 2024. “While our results for the year demonstrate some improvement due to cost control, and the inclusion of or commercial lending business acquisition, the fourth quarter and full year results reflect continued pressures on Revenues and Earnings across our industry that began in the fall of 2022 and continued well into calendar 2024. Capital Markets activity continues to be weaker than expected. On the bright side our commercial lending activities provided some optimism for 2025 and beyond,” said Hampton Executive Chairman & CEO Peter Deeb. Fourth Quarter IFRS Results highlights: Fourth Quarter ended August 31st, 2024; Q4 Revenues of $3,351,000; an increase of 51% year-over-yearQ4 Net Losses of ($1,925,000) or $(0.04) per share; Full Year IFRS Results highlights: Fiscal Year ended August 31st, 2024; FY Revenues of $9,794,000; an increase of 12% year-over-yearFY Net Losses of ($2,740,000) or $(0.07) per share; Full Year fiscal Result (Adjusted for Non-Recurring & Non-Cash Items) highlights: Fiscal Year ended August 31st, 2024; FY Adjusted Net Losses of ($1,186,000) or $(0.02) per share; FY EBITDA of ($535,000) vs ($1,395,000) for the fiscal year 2023 Summary of Corporate Developments: Our 4th Quarter and full-year results reflect the challenging year that was 2024 for our industry as a whole. Rising interest rates and global uncertainty continue to delay many financings and broader financial decisions on the part of issuers, which negatively impacts our Corporate Finance business. While 2024 showed some signs of improvement, the year ahead for our core businesses looks somewhat unclear. That said we intend to move ahead with a number of initiatives to further expand our business portfolio, while growing our existing Wealth Management, Capital Markets businesses and Commercial Lending operations. We are hopeful for an improved 2025. The Company, through its wholly owned subsidiary, Hampton Securities Limited (“HSL”) continues to develop its Wealth Management, Advisory Team and Principal-Agent programs which offers the industry’s most experienced wealth managers a unique and flexible operating platform that provides additional freedom, financial support, and tax effectiveness as they build and manage their professional practice. Our Corporate Finance Group provides early stage, growing companies the capital, they need to create value for investors. Our Treasury Group works to maximize returns from our balance sheet and strengthen our competitive position as one of Canada’s leading independent financial institutions. The company’s wholly owned commercial lending business, Oxygen Working Capital Corp. (OXY), provides factoring and term financing to businesses across Canada. Copies of Hampton’s unaudited interim financial statements and its Management’s Discussion & Analysis for the fiscal year ended August 31st, 2024 can be accessed on SEDAR at www.sedar.com. About Hampton Financial Corporation Hampton is a unique private equity firm that seeks to build shareholder value through long-term strategic investments. Through HSL, Hampton is actively engaged in family office, wealth management, institutional services and capital markets activities. HSL is a full-service investment dealer, regulated by IIROC and registered in Alberta, British Columbia, Manitoba, Saskatchewan, Nova Scotia, Northwest Territories, Ontario, and Quebec. In addition, the Company provides investment banking services, which include assisting companies with raising capital, advising on mergers and acquisitions, and aiding issuers in obtaining a listing on recognized securities exchanges in Canada and abroad. The company is also engaged in the Commercial Lending space through its wholly owned subsidiary, Oxygen Working Capital. The company continues to explore opportunities to diversify its sources of revenue by way of strategic investments in both complimentary business and non-core sectors that can leverage the expertise of its Board and the diverse experience of its management team. For more information, please contact: Olga JuravlevChief Financial OfficerHampton Financial Corporation(416) 862-8701 Or Peter M. DeebExecutive Chairman & CEOHampton Financial Corporation(416) 862-8651 The TSXV has in no way approved nor disapproved the contents of this press release. Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release. No securities regulatory authority has either approved or disapproved of the contents of this press release. This press release does not constitute or form a part of any offer or solicitation to buy or sell any securities in the United States or any other jurisdiction outside of Canada. The securities being offered have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or the securities laws of any state of the United States and may not be offered or sold within the United States or to a U.S. person absent registration or pursuant to an available exemption from the registration requirements of the U.S. Securities Act and applicable state securities laws. There will be no public offering of securities in the United States. Forward-Looking Statements This press release contains certain forward-looking statements and forward-looking information (collectively referred to herein as "forward-looking statements") within the meaning of applicable Canadian securities laws, which may include, but are not limited to, information and statements regarding or inferring the future business, operations, financial performance, prospects, and other plans, intentions, expectations, estimates, and beliefs of the Company. All statements other than statements of present or historical fact are forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “should”, “hopeful”, “recovery”, "anticipate", "achieve", "could", "believe", "plan", "intend", "objective", "continuous", "ongoing", "estimate", "outlook", "expect", "may", "will", "project" or similar words, including negatives thereof, suggesting future outcomes. Forward-looking statements involve and are subject to assumptions and known and unknown risks, uncertainties, and other factors beyond the Company’s ability to predict or control which may cause actual events, results, performance, or achievements of the Company to be materially different from future events, results, performance, and achievements expressed or implied by forward-looking statements herein. Forward-looking statements are not a guarantee of future performance. Although the Company believes that any forward-looking statements herein are reasonable, in light of the use of assumptions and the significant risks and uncertainties inherent in such statements, there can be no assurance that any such forward-looking statements will prove to be accurate. Actual results may vary, and vary materially, from those expressed or implied by the forward-looking statements herein. Accordingly, readers are advised to rely on their own evaluation of the risks and uncertainties inherent in forward-looking statements herein and should not place undue reliance upon such forward-looking statements. All forward-looking statements herein are qualified by this cautionary statement. Any forward-looking statements herein are made only as of the date hereof, and except as required by applicable laws, the Company assumes no obligation and disclaims any intention to update or revise any forward-looking statements herein or to update the reasons that actual events or results could or do differ from those projected in any forward-looking statements herein, whether as a result of new information, future events or results, or otherwise, except as required by applicable laws.
Practical Examples of How ERTC Loans Can Help Your Business - TechBullion
Business finance offers various tools to support growth and resilience, and Employee Retention Tax Credit (ERTC) loans have become a vital resource for businesses facing uncertainty. These government-backed loans provide key financial support, allowing companies to sustain operations, retain employees, and tackle challenges with confidence. An ERTC loan is more than a short-term solution—it offers […]
Budget 2025 Expectations Live: ICEA calls for ₹40,000 crore financial support from government for electronics manufacturing - The Hindu BusinessLine
India Union Budget 2025, Budget 2025-26 Expectations Live Updates: The Union Budget for 2025-26 will be presented by Finance Minister Nirmala Sitharaman on February 1, 2025. Budget announcements will gain importance as it comes in the middle of what observers call a cyclical slowdown for the Indian economy. Consumption spending is slowing as has capital expenditure, both private and public. Industry captains will look for signs of a step up in government capital spending.
BellaSeno Successfully Completes Two Clinical Trials with Novel, Resorbable Breast Implants - ForexTV
One-year follow-up data confirm favorable safety profile of BellaSeno´s scaffolds compared to silicone implantsCompany plans expansion to primary breast augmentation and lumpectomy Leipzig, Germany/ Brisbane, Australia, January 14, 2025 – BellaSeno GmbH, an ISO 13485-certified medtech company developing resorbable scaffolds using additive manufacturing technologies, today announced that all 19 breast scaffold patients enrolled in 2022 in an Australian breast augmentation revision trial have successfully completed a one-year follow-up without any major scaffold-related complications or scaffold removals. In addition, in a parallel Australian clinical trial, 7 pectus excavatum patients have successfully passed one-year follow-up. The trials are the first-ever implant trials using a novel approach combining polycaprolactone (PCL) scaffolds, ultimately resulting in a fully resorbed implant and natural tissue. The data show that it is possible to replace silicone implants in breast augmentation with alternatives offering improved safety and quality of life. The trials are sponsored, single-arm, open, mono-centric, interventional, prospective clinical investigation studies in patients requiring breast augmentation revisions or surgical pectus excavatum correction. Primary endpoint is post-operative device safety, secondary endpoints is post-operative patient safety and post-operative device performance (QOL, volume replacement). The one-year assessment confirms a very favorable safety profile of BellaSeno´s resorbable soft tissue implants. No major complications such as capsular contracture, calcifications, oil cysts, infections, tissue necrosis, or wound healing issues were observed. No scaffold removals or replacements were necessary, and no scaffold-related complications were observed in any patients six months post-surgery. The one-year data review by the Independent Data Safety Monitoring Committee stated that all adverse events were within the expected range of complications for removal / replacement surgeries. The Clinical Investigators reported higher patient satisfaction with breasts and quality of life associated with BellaSeno´s scaffolds compared to baseline (i.e. silicone implants). There was high acceptability; patients were pain-free and did not report awareness of the scaffold in situ after twelve months. Identical findings were made in the one-year follow up in pectus excavatum patients. “This is a very encouraging one-year clinical outcome,” said Mohit Chhaya, CEO of BellaSeno. “The data confirm that our resorbable scaffolds do not only meet the desired safety criteria but also show an improvement of patients´ quality of life. We now have a very strong clinical data set to initiate a pivotal study of our resorbable breast scaffolds in the U.S. and Europe. We will also expand the use of our scaffolds to primary breast augmentation and lumpectomy and also provide a final two-year follow-up next year.” ### About BellaSenoBellaSeno GmbH was founded in 2015 and is headquartered on the BioCity campus in Leipzig, Germany, with a subsidiary in Brisbane, Australia. The Company is developing novel resorbable soft tissue and bone reconstruction implants made by additive manufacturing (3D-printing) under ISO 13485 certification. The Company has received substantial financial support from private investors as well as from the Saxony Development Bank (SAB), the European Fund for Regional Development (EFRE), Germany´s Federal Ministry of Education and Research (BMBF) and the Australian government. The Company has been co-funded from tax resources based on the budget adopted by the members of Saxony State Parliament. Contact BellaSenoBellaSeno GmbHDr. Mohit Chhayamohit.chhaya@bellaseno.comTel.: +49 176 2283 9583 Media InquiriesakampionDr. Ludger Wess / Ines-Regina Buth Managing Partnersinfo@akampion.comTel. +49 40 88 16 59 64Tel. +49 30 23 63 27 68
Donation vexation: FTC and 10 States challenge cancer “charity” as a sham | Federal Trade Commission
Think about the two women across from you in the office. Now consider the sobering statistic that of those two women, one will battle cancer in her lifetime. The bad news gets worse when you realize there are sham charities out there that claim to offer financial assistance for people undergoing cancer treatment, but then spend donations for other purposes. The FTC and 10 states just sued Cancer Recovery Foundation International (also known as Women’s Cancer Fund) and Gregory B. Anderson, alleging the defendants collected $18 million from generous Americans between 2017 and 2022 while providing only $194,809 in financial support for cancer patients – literally about a penny of every donated dollar. According to the lawsuit, Anderson pocketed $775,139, nearly four times more than what the “charity” gave collectively to women battling cancer. But hold on to your hat – and your wallet – when you learn where the FTC and the States say the rest of the money went.